Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells
References (42)
- et al.
Biochim. biophys. Acta
(1983) - et al.
Biochem. Pharmac.
(1979) - et al.
Analyt. Biochem.
(1979) - et al.
Analyt. Biochem.
(1977) - et al.
J. Biochem. Biophys. Meth.
(1980) - et al.
Biochem. Pharmac.
(1983) - et al.
Lymphokines
(1982) Ann. Rheum. Dis.
(1983)Agents Actions
(1980)Scand. J. Rheumatol. (Suppl.)
(1981)
Agents Actions
Scand. J. Rheumatol. (Suppl.)
Arthritis Rheum.
Clin. exp. Immun.
J. Rheumat. (Suppl.)
J. Rheumat.
Ann. Rheum. Dis.
Calc. Tiss. Res.
Arthritis Rheum.
Experientia
Cited by (32)
Bisphosphonates: Pharmacology and clinical approach to their use in equine osteoarticular diseases
2014, Journal of Equine Veterinary ScienceCitation Excerpt :In recent articles, the use of BPs as metalloproteinase inhibitors has been suggested [77–79], and it has been demonstrated that in vitro tiludronate can inhibit the activity of matrix metalloproteinases (MMP-1 and MMP-3), thus supporting the idea that one of the mechanisms by which BPs accomplish their effect is by chelating cations that are used as enzyme cofactors [80]. In another in vitro study [81], tiludronate was able to inhibit the interleukin (IL) 1–mediated secretion of cartilage matrix–degrading enzymes by chondrocytes and synovial cells. In a dog anterior cruciate ligament transaction model follow by reconstructive surgery, the cartilage volume loss was greatly prevented and concomitant treatment with tiludronic acid provided an additional benefit reducing experimental OA lesions [82].
Pharmacotherapy of joint and tendon disease
2013, Equine Sports Medicine and Surgery: Second EditionExtra-skeletal effects of bisphosphonates
2007, Joint Bone SpineCitation Excerpt :BPs stimulate chondrocyte proliferation in rabbits [55] and induce direct metabolic chondrocyte alterations, such as increased synthesis of collagen and proteoglycans, as described in several studies [56]. Chloro-4-phenyl-thiomethylene bisphosphonate (SR 41319) and, to a lesser extent, etidronate inhibit the secretion of several matrix metalloproteinases (MMPs), such as collagenase, proteinase acting on caseine, and proteoglycans, from joint chondrocytes and synoviocytes stimulated by macrophage colony-stimulating factor (MCS-F) [57]. Pamidronate and risedronate inhibit apoptosis and growth impairment induced by dexamethasone in cultured chondrocytes suggesting a chondroprotective effect of the amino-BPs during corticosteroid treatment [58].
The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage
2002, Osteoarthritis and Cartilage